Clinical Trial Results Comparison Three landmark Phase 3 trials provide the comparison data
Vn chuyn ni bo thng qua s hp nht mng t bo V cu trc ca liposome tng t nh mng t bo ngi, chng c th gn trc tip vo cc t bo ch
1).29,32 With respect to the vascular system, rGLP-1 activation induces modest decreases in blood pressure,33,34 it has a vasodilator effect, improves arterial stiffness, and prevents atherosclerotic plaque formation-and has plaque stabilizing effects-through its anti-inflammatory and antiapoptotic effects as demonstrated in animal models.29,32,3538 Despite controversies about rGLP-1 expression in vascular smooth muscle and endothelial cells, studies have shown that arGLP-1 has antiproliferative effects on these cells,39 reduces oxidative stress, improves endothelial function, and increases nitric oxide production in experimental models.3540 In the heart they produce a discrete increase in heart rate (24 beats/min), although this does not seem to be associated with an increase in arrhythmias or cardiovascular events

Here are the drugs they reviewed: Other conditions now being evaluated for GLP-1 effectiveness include: Parkinsons Disease Alzheimers dementia Alcohol use disorder These drugs are also being evaluated for obsessive-compulsive disorder, opioid use disorder, gambling, and other mental health diagnoses, although these are not mentioned in this review
Growth hormone secretion patterns shift